This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ichikawa, Y. Articles by Miwa, M. Search for Related Content PubMed PubMed Citation Articles by Ichikawa, Y. Articles by Miwa, M.

Mutation of K-ras Protooncogene Is Associated with Histological Subtypes in Human Mucinous Ovarian Tumors¹

Department of Biochemistry, Institute of Basic Medical Sciences [Y. L., H. S., S. Y, K. U., M. M.]; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba [M. N., H. T, Z K.], Tsukuba 305, Japan

² To whom requests for reprints should be addressed, at Institute of Basic Medical Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305, Japan.

A series of 57 mucinous and 47 serous ovarian tumors (adenomas, tumors of borderline malignancy, and carcinomas) were examined by polymerase chain reaction-single strand conformation polymorphism analysis and direct sequencing for mutations in codons 12, 13, and 61 of K-ras gene. Higher incidence of K-ras mutations was observed in mucinous tumors compared to serous ones. Mutations were detected in 4 of 30 mucinous adenomas (13%), in 4 of 12 mucinous tumors of borderline malignancy (33%), and in 7 of 15 mucinous carcinomas (46%). Only 1 of 17 serous carcinomas (6%) had a mutation of K-ras in serous ovarian tumors. All mutations identified were in codon 12. Detailed analysis revealed that more K-ras mutations in mucinous adenomas were observed in intestinal type (identified in 4 of 13) than in endocervical type (identified in 0 of 17). Thus, K-ras gene codon 12 mutations in mucinous ovarian adenomas appear to be associated with the occurrence of intestinal type adenomas.

¹ This study was supported in part by Grants-in-Aid for Scientific Research, Cancer Research, and Tsukuba Project Research from the Ministry of Education, Science and Culture, Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/12/93. Accepted 11/12/93.

This article has been cited by other articles:

				G. Yang, D. G. Rosen, Z. Zhang, R. C. Bast Jr., G. B. Mills, J. A. Colacino, I. Mercado-Uribe, and J. Liu The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis PNAS, October 31, 2006; 103(44): 16472 - 16477. [Abstract] [Full Text] [PDF]

				F. W. Wamunyokoli, T. Bonome, J.-Y. Lee, C. M. Feltmate, W. R. Welch, M. Radonovich, C. Pise-Masison, J. Brady, K. Hao, R. S. Berkowitz, et al. Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance Clin. Cancer Res., February 1, 2006; 12(3): 690 - 700. [Abstract] [Full Text] [PDF]

				I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]

				R. T. Marquez, K. A. Baggerly, A. P. Patterson, J. Liu, R. Broaddus, M. Frumovitz, E. N. Atkinson, D. I. Smith, L. Hartmann, D. Fishman, et al. Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon Clin. Cancer Res., September 1, 2005; 11(17): 6116 - 6126. [Abstract] [Full Text] [PDF]

				G. Fabjani, G. Kriegshaeuser, A. Schuetz, L. Prix, and R. Zeillinger Biochip for K-ras Mutation Screening in Ovarian Cancer Clin. Chem., April 1, 2005; 51(4): 784 - 787. [Full Text] [PDF]

				T. W. Young, F. C. Mei, G. Yang, J. A. Thompson-Lanza, J. Liu, and X. Cheng Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry Cancer Res., July 1, 2004; 64(13): 4577 - 4584. [Abstract] [Full Text] [PDF]

				I.-M. Shih and R. J. Kurman Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis Am. J. Pathol., May 1, 2004; 164(5): 1511 - 1518. [Abstract] [Full Text] [PDF]

				J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al. A Genetically Defined Model for Human Ovarian Cancer Cancer Res., March 1, 2004; 64(5): 1655 - 1663. [Abstract] [Full Text] [PDF]

				V. Bazan, M. Migliavacca, I. Zanna, C. Tubiolo, N. Grassi, M. A. Latteri, M. La Farina, I. Albanese, G. Dardanoni, S. Salerno, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann. Onc., September 1, 2002; 13(9): 1438 - 1446. [Abstract] [Full Text] [PDF]

				A. B. Spurdle, P. M. Webb, D. M. Purdie, X. Chen, A. Green, and G. Chenevix-Trench Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype Carcinogenesis, January 1, 2001; 22(1): 67 - 72. [Abstract] [Full Text] [PDF]